

DR JOHN EDEN MB BS MD FRCOG FRANZCOG CREI

Dr John Eden is a certificated reproductive endocrinologist and gynaecologist. He is a Conjoint Associate Professor at The University of New South Wales in Sydney. He is a visiting medical officer at the Royal Hospital for Women, Sydney, Australia where he is Director of the Sydney Menopause Centre and the Barbara Gross Research Unit. He also works at the Moree Aboriginal Health Service and is a Director of the Women's Health and Research Institute of Australia (WHRIA). His research and clinical interests include managing menopause after breast cancer, infertility, early menopause, polycystic ovary syndrome (PCOS), amenorrhoea, osteoporosis, PMDD, biofilms, hormone replacement therapy as well as herbal medicine.

This article discusses management options for vaginal atrophy and the importance of considering these in women for optimal sexual function.

Introduction

Vulvovaginal dryness is a common problem after the menopause. It can lead to painful sexual intercourse, vulval irritation and may contribute to bladder problems, such as recurrent urinary tract infections. Studies have shown that many Australian women do not recognise it as a treatable medical condition.¹ One recent Australian survey showed that only 5% of women aged sixty to sixty-five years were using the most effective treatment, that is topical oestrogen.¹ The International Menopause Society recently reviewed its guidelines for managing menopause.^{2,3} Regarding vaginal atrophy, the Guidelines state: 'There are considerable data to support their (topical oestrogens) use in urogenital atrophy.'²

This short review will examine the normal physiology of the vagina and the impact of menopause on genitourinary atrophy. Effective therapies for this distressing problem will also be discussed.

Normal Physiology of the Vagina

The vagina is a fibromuscular tube lined by epithelium. It joins the cervix and uterus posteriorly to the vulva at front.^{4,5} The

Take Home Messages

- ✔ There are considerable data to support the use of topical oestrogens in urogenital atrophy.
- ✔ Topical oestrogens should not be deposited deep in the vagina, but rather in the anterior portion, in order to minimise uterine exposure and to maximise the effect on the vulva, urethra and clitoral areas.
- ✔ Oestrogen creams may be best used by abandoning the applicator all together and placed on a finger instead. This is then inserted inside the anterior vagina; some cream should also be smeared onto the vulval skin.
- ✔ Patients who have had breast cancer should use non-hormonal moisturisers first and topical oestrogen as a last-resort.
- ✔ Vulval dryness may respond to soap-free washes, using plain moisturisers on the vulva and intravaginal moisturiser products. Natural oils (such as coconut oil or olive oil) can be effective lubricants.

anterior portion of the vagina has markedly different properties to the posterior vagina, reflecting their differing embryological origins. The anterior vagina arises from the urogenital sinus and the posterior vagina from the Mullerian ducts.⁵ Interestingly, the anterior vagina, clitoris and urethra all share a common blood supply and innervation (the anterior branch of the pudendal nerve). The vulva, vagina and clitoris are all covered in squamous epithelium. During sexual arousal, engorgement of all these regions occurs.⁵ There is a complex network of blood vessel surrounding the vagina, especially anteriorly. As shown in the Figure 1, the clitoral vascular unit surrounds the vulva on both sides.




Figure 1. Anatomy of the vulva and clitoris
(with credit to Amphis, Licence no. CC-BY-SA 1.0)

During sexual arousal, the vaginal and urethra both release secretions⁵ that make penetrative intercourse much more comfortable for the woman. It has been shown that water transfer across the vaginal mucosa is controlled by specific conduits called ‘aquaporin water channels’.⁶ The pelvic floor muscles support the

vagina, bladder and rectum and also play an important role in sexual function.^{4,5} All these structures (the clitoris, the pelvic floor muscles and the vaginal epithelium) have sex-hormone receptors (mostly oestrogen receptors; some parts of the pelvic floor muscles have androgen receptors).⁷⁻¹⁰




Figure 2. Diagram of vaginal epithelium of a reproductive aged woman. Note the thick superficial epithelial layer.
(© Dr. A. L. Neill www.amandasatoz.com)

During the reproductive years, the vaginal epithelium is thick and moist, in response to stimulation by oestrogen (see Figure 2).

After menopause, the vaginal epithelium markedly thins¹¹ (see Figure 3), as does the supporting vaginal tissue. This atrophic epithelium often cannot support sexual intercourse and this then becomes dry and painful. Topical oestrogens are very effective at reversing the problem.¹¹




Figure 3. Diagram of vaginal epithelium of an untreated, postmenopausal woman. Note the thinning of the superficial epithelial layer.
(© Dr. A. L. Neill www.amandasatoz.com)

Finally, the healthy vagina has a symbiotic relationship with several bacteria, most notably, lactobacillus¹²⁻¹⁴ and typically, one or two species dominate. These bacteria produce lactic acid that helps to maintain an acidic environment within the vagina. This aids the reduction of pathological microorganisms. Interestingly, there are data to suggest that cross-species chemically communicate with each other.¹⁴ It seems likely that the healthy vaginal epithelium releases chemical signals, ‘attracting’ the right species of lactobacillus.

ADVERTISEMENT

Addressing relief for vaginal atrophy¹⁻⁴ **Ovestin** oestriol



Refer to primary advertisement on page 4 for PBS listing and Product Information (PI). Review PI before prescribing.

Aspen Australia, St. Leonards, NSW 2065. Prepared: February 2017.

Table. The Vagina as a Delivery System.¹⁶

- ✔ The vagina is a primary target for sex hormones and so topical hormone therapies can affect the vagina directly.
- ✔ Some vaginal delivery systems have systemic effects (e.g. NuvaRing®) because of exposed surface area and positioning.
- ✔ The vagina has a large surface area (around 95cm²) and has an extensive surrounding venous plexus that is in close proximity to the vaginal arterial supply. In the upper vagina, veins merge into the uterovaginal plexus that eventually drains into the iliac vessels. The anterior vaginal veins merge into the haemorrhoidal and pudendal internal plexus. This difference partially explains the difference in medication distribution, depending upon where in the vagina the medication is placed.
- ✔ Absorption across the vagina is governed by factors such as the molecular weight of the medication, liposolubility, duration and surface area of exposure.
- ✔ The concentration gradient between medication and blood is a primary determinant of absorption through the vaginal wall. Thus, for example, the absorption of two caps of progesterone 100mg via the vaginal epithelium is not exactly the same as one cap of progesterone 200mg.
- ✔ Physiological factors, such as the phase of the menstrual cycle and the vaginal pH will alter absorption.
- ✔ Compared to the intestinal epithelium, the vagina has low metabolic activity. Compared to oral administration, vaginal delivery of progesterone, for example, results in

higher serum levels and a more potent uterine effect, while levels of 5 α and 5 β metabolites are lower. This leads to fewer side-effects (such as sedation and moodiness) with vaginal administration of progesterone compared to oral administration.

- ✔ Steroids absorbed through the vagina may have two different pathways:

a. Systemic:

Rapid absorption (e.g. progesterone in oil administered via the vagina results in peak serum levels one to two hours after administration, followed by more sustained levels when compared to oral administration). Avoidance of hepatic first-pass metabolism results in a greater bioavailability of the medication with little metabolism, hence there is minimal impact on liver proteins such as clotting factors.¹⁶

b. Regional distribution:

- i. Uterine-first-pass effect: drugs delivered to the upper third of the vagina tend to pass directly to the uterus. This is largely due to a sharing of upper vaginal vessels and uterine vessels.¹⁶ For example, the plasma levels of vaginally administered progesterone are higher in the uterine arteries than in the radial arteries.¹⁶
- ii. Preferential distribution to the pelvis: Vaginal danazol is an effective treatment for endometriosis because the drug is preferentially distributed to the uterine, broad ligament, ovarian and utero-ovarian pedicles.
- iii. Topical medications placed in the lower third of the vagina are delivered to the periurethral, vulval and clitoral areas.

Lactobacilli also produce hydrogen peroxide, hydroxyl radicals and probiotics, all of which help to control the vaginal microbiome.¹²⁻¹⁴ After menopause, the lactobacilli usually disappear and the vagina tends to be colonised by bowel flora (such as *E. coli*).¹²⁻¹⁴

In summary, much of the female sexual response is regulated by oestrogens, although androgens also have an important role. The untreated postmenopausal state typically results in vulvovaginal thinning and loss of lubrication, resulting in painful intercourse.

The Vagina as a Delivery System

Cicinelli and colleagues have performed a number of studies examining the concept of the vagina as a delivery system.¹⁵⁻¹⁷ Some of the pharmacokinetics of the vaginal route of delivery are summarised in the Table.¹⁶

In an elegant study, Cicinelli studied six women undergoing abdominal hysterectomy.¹⁷ Three had their cervixes sealed with surgical glue (to prevent transcervical transmission of medication).

Each of the six had 0.2cc ^{99m}Tc-pertechnetate deposited in the upper third of the vagina and they were then placed in a nuclear medicine scanner. Evidence of radioisotope uptake in the uterus appeared after sixty minutes and peaked at approximately one hundred and twenty minutes to two hundred and ten minutes. The authors concluded that preferential vagina-to-uterus distribution is largely mediated by a counter-current vascular transfer mechanism, and not via the cervix.

The authors also studied Vagifem® (25mcg oestradiol vaginal tablets) and its positioning in different sites (either the upper or the lower third of the vagina).¹⁵ They then investigated the impact on the uterine blood vessels (using Doppler) and also documented the systemic levels of oestradiol.¹⁵ Oestradiol tablets placed in either vaginal position resulted in small, but significant rises in serum oestradiol levels. Placement of oestradiol in the upper vagina resulted in a significant decrease in pulsatility and resistance index of the uterine arteries, consistent with an oestrogenic effect. No such effect was seen with placement in the anterior vagina. They concluded that topical oestrogens should not be deposited deep in

Addressing relief for vaginal atrophy¹⁻⁴

Ovestin[®]
oestriol

only about 25% of women suffering from vaginal atrophy symptoms actually volunteer the information to their health-care professional⁵



Before prescribing please review full Product Information available on request from Aspen Australia or at www.aspenpharma.com.au/products

PBS Information: Ovestin Cream and Ovestin Ovula are listed on the PBS as an oestrogen. Ovestin Tablet is not listed on the PBS.

Minimum Product Information – Ovestin (oestriol) Tablets, Cream and Ovula - INDICATIONS: *Tablets:* Short-term treatment of menopausal syndrome. *Cream and Ovula:* Vulvo-vaginal complaints due to oestrogen deficiency associated with the climacteric and postmenopause or after ovariectomy; atrophic vaginitis; pruritus vulvae; dyspareunia due to vulvo-vaginal atrophy; auxiliary therapy in the treatment of vaginal infections; pre-operative therapy for vulvo-vaginal surgery and during subsequent convalescence; ulcers in cases of prolapse of the uterus or vagina; to avoid misinterpretation of a cytological smear. **CONTRAINDICATIONS:** Pregnancy (Cat. B1); lactation; known, past or suspected breast cancer; known or suspected oestrogen-dependent malignant tumours; undiagnosed genital bleeding; previous or current active VTE (DVT, pulmonary embolism); known thrombophilic disorders; history of recurrent VTE or known thrombophilic disease in a patient who is not already on anticoagulant treatment; active or recent arterial thromboembolic disease; current or history of thrombophlebitis; history during pregnancy or previous use of steroids of a manifestation or deterioration of otosclerosis; endometriosis; untreated endometrial hyperplasia; porphyria; severe liver dysfunction or history of liver disease; disturbed lipid metabolism; hypersensitivity to oestriol or any excipients (see full PI). **PRECAUTIONS:** leiomyoma; history of or risk factors for thromboembolic disorders; risk factors for oestrogen dependent tumours; hypertension; liver disorders; diabetes mellitus; cholelithiasis; migraine or severe headache; systemic lupus erythematosus; history of endometrial hyperplasia; epilepsy; asthma; otosclerosis; severe pruritus; cholestatic jaundice; herpes gestationis; coronary artery disease; smoking; ischaemic stroke; ovarian cancer; fluid retention; cardiac or renal dysfunction; gall bladder disease; uterine fibroids; epilepsy; asthma; fibrocystic mastopathy; metabolic bone disease; dementia; lactation (see full PI). **INTERACTIONS:** corticosteroids; succinylcholine; theophyllines; troleandomycin; oral anticoagulants; inducers of drug-metabolizing enzymes e.g. anticonvulsants, barbiturates, anti-infectives, antiretroviral agents, St John's wort (see full PI). **ADVERSE EFFECTS:** *Tablets:* fluid retention; nausea; breast discomfort and pain; postmenopausal spotting; cervical discharge; flu-like symptoms. *Cream and Ovula:* local irritation or itching (see full PI). **DOSAGE AND ADMINISTRATION:** *Tablets:* Swallow with food at the same time each day. Initially up to 4mg daily for 5-7 days then 1-2mg daily thereafter as maintenance. *Cream:* For intravaginal administration at night using a calibrated applicator (each application-dose is 0.5g of Ovestin cream containing 0.5mg oestriol). *Vulvo-vaginal complaints associated with menopause:* Initially, one application-dose per day for 3 weeks then one application twice weekly thereafter as maintenance (discontinue therapy every 2-3 months for 4 weeks to review need for further treatment). *Pre-surgery therapy:* one application-dose per day beginning 2 weeks before operation. *Suspect cytological smear:* one application-dose per day for 7 days before re-evaluating. *Ovula:* For intravaginal administration, at night. *Vulvo-vaginal complaints associated with menopause:* initially one pessary daily for 2-3 weeks, then one pessary once or twice a week thereafter as maintenance (discontinue every 2-3 months for 4 weeks to assess need for further treatment). *Pre-surgery therapy:* one pessary daily, beginning 2 weeks before operation. *Suspect cytological smear:* one pessary daily for 7 days before re-evaluation (See full PI for full instructions on administration, missed doses and switching from HRT). (Based on PI last amended: 06/07/2016)

References: 1. Ovestin Cream Approved Product Information 6 July 2016 2. Ovestin Pessary Approved Product Information 6 July 2016 3. Ovestin Tablets Approved Product Information 6 July 2016 4. Suckling et al. 2006, Local oestrogen for vaginal atrophy in postmenopausal women (review). Cochrane Collaboration 5. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy – on behalf of the International Menopause Society Writing Group. *Climacteric* 2010;Early Online, 1-14

All sales and marketing requests to: **Aspen Pharmacare Australia Pty Ltd**, ABN 51 096 236 985, 34-36 Chandos Street, St Leonards, NSW 2065
Tel +61 2 8436 8300 aspen@aspenpharmacare.com.au www.aspenpharma.com.au

Aspen Australia is comprised of Aspen Asia Pacific Pty Ltd (ABN 75 146 444 484) and its subsidiaries, including Aspen Pharmacare Australia Pty Ltd (ABN 51 096 236 985), Aspen Pharma Pty Ltd (ABN 88 004 118 594), Aspen Nutritionals Australia Pty Limited ACN 160607509, Orphan Holdings Pty Ltd (ABN 50 115 816 209), Orphan Australia Pty Ltd (ABN 11 067 189 342) and Aspen Products Pty Ltd (ABN 17 003 144 170). Prepared: February 2017. AF01649 ASP1562



the vagina, but rather in the anterior portion, in order to minimise uterine exposure and to maximise the effect on the vulva, urethra and clitoral areas.

Vaginal Hormone Therapies

Rahn has performed a meta-analysis of vaginal oestrogens for genitourinary symptoms after menopause.¹⁸ He concluded that they are all effective and seem safe. He found some studies comparing vaginal moisturisers and topical oestrogens; the oestrogen products were significantly more effective.

As previously discussed, it seems prudent to instruct patients to place topical oestrogens in the anterior portion of the vagina. Creams such as Ovestin[®] may be best used by abandoning the applicator all together and suggesting that the patient place about a square centimetre of cream on a finger. They should then place that finger inside the vagina and smear the rest of the product onto the vulval skin. The Vagifem[®] introducer should probably not be placed deep inside the vagina, but rather, only about three to five centimetres inside. Both products are probably best used at night to avoid external spillage.

There is some controversy about the use of topical oestrogens after a diagnosis of breast cancer.¹⁹ The American College of

Obstetricians and Gynecologists suggests that such patients use non-hormonal moisturisers first and that topical oestrogen be used as a last-resort.¹⁹ Topical dehydroepiandrosterone (DHEA) or laser therapy may be a better option for these patients.

Pharmaceutical grade topical DHEA is not yet available in Australia.

Topical DHEA (6.5mg daily delivered as a pessary) has been shown to convert to oestrogen. This then acts on the vagina without any systemic effect on serum oestrogen or androgen levels. Measurements were performed by very sensitive technology (mass-spectrometry).^{20,21} Pharmaceutical grade topical DHEA is not yet available in Australia. Laser therapy is discussed below.

Non-hormonal Therapies for Vaginal Atrophy

Many Australian women wash with soap and this has marked drying properties. Some obtain relief from vulval dryness by simply bathing with soap-free washes, using plain moisturisers on the vulva and sometimes intravaginal moisturiser products (such as Replens[®]). Natural oils (such as coconut oil or olive oil) can be effective lubricants. Some women who have put up with marked

ADVERTISEMENT

Addressing relief for vaginal atrophy¹⁻⁴

Ovestin[®]
oestriol

only about 25% of women suffering from vaginal atrophy symptoms actually volunteer the information to their health-care professional⁵



Refer to primary advertisement on page 4 for PBS listing and Product Information (PI). Review PI before prescribing.

Aspen Australia. St.Leonards, NSW 2065.Prepared: February 2017.

Video Resources

Genitourinary Syndrome of Menopause (GSM)
Menopause, Vol. 27, No. 10, 2014

Anatomy	Descriptors	Problem	Life Phase
Vagina	Vulvovaginal	Atrophy	Midlife
Vulva	Genital	Alterations	Aging
Labia	Gynecologic	Changes	Menopause
Vestibule	Reproductive	Condition	Perimenopause
Urethra	Sexual	Disease	Postmenopause
Bladder	Urogenital	Disorder	
	Genitourinary	Deficiency	
	Urinary	Dysfunction	
	Urologic	Syndrome	
		Vaginitis	

Terms in bold are the words selected by the panel to develop new nomenclature.

www.healthed.com.au

New Approaches for Management of Vulvovaginal Atrophy by Dr Marcus Carey

Neurophysiology

- The vaginal vestibule has the same origin as the urethra and the bladder (less E2 receptors)
- The nerve supply of the vulva is redundant, but dominated by the branches of the pudendal nerve

Types of Peripheral Nerve Fibers (all afferent)

- A-beta Fibers: Vibration and pressure, Afferent transmission
- A-delta Fibers: Cold sensation + Fast pain and localized touch
- C Fibers: Hot sensation + Slow pain and generalized touch

A-delta fibers are predominant in the vagina and cervix and to some degree in the vestibule. A-delta fibers (Pain) Fast Pain Speed of 5-25 m/sec. C fibers are well represented in the vagina and cervix and to some degree in the vestibule. C fibers (Pain) Slow Pain Speed of 0.7-2.0 m/sec. A-beta fibers (Sensory) Pain Speed of 30-70 m/sec. Dorsal Root Ganglion.

www.healthed.com.au

New Developments in the Management of Vaginal Atrophy & Dyspareunia by Dr Fariba Willison

WHRIA New Approaches for VVA

Vulvovaginal Atrophy
The Extent of the Problem

- Menopause related urogenital symptoms affects >50% of midlife and older women
- Sexuality is an important part of life
- Inadequate communication regarding female sexual health issues in the clinical setting
- REVIVE (Real Women's Views of Treatment Options for Menopausal Vaginal Changes) Survey 2013, postmenopausal women reported only
 - 19% health care professionals addressed patient's sexual lives
 - 13% specifically raised the issue of genitourinary symptoms
- CLOSER (Clarifying Vaginal Atrophy's Impact on sex and Relationships) Survey 2014
 - <50% were aware of available treatments (nonhormonal/hormonal) to improve vaginal discomfort

www.healthed.com.au

Vulvovaginal atrophy by Dr Yasmin Tan

The symptoms of menopause

- Central: Hot flushes & night sweats; insomnia; mood and memory changes
- Joint aches & muscle pains
- Urogenital: Dry vagina/dyspareunia; urinary frequency, UTI, incontinence
- Skin: Dryness, thinning, loss elasticity, crawling under the skin, acne
- Hair: increased facial hair, thinning scalp & pubic hair
- Loss of libido
- Long term consequences: metabolic, cardiovascular, bone & brain

How long do they last?
 •20% have few or no symptoms
 •60% have 4 - 8 years of symptoms
 •20% may have severe symptoms that continue into their 60s and 70s

www.healthed.com.au

Menopause Management Update by Prof Bronwyn Stuckey

Watch full lectures on the Healthed website. Visit www.healthed.com.au/video

vaginal dryness for years develop pelvic floor myalgia (spasm). This can be usually managed by referral to a pelvic floor physiotherapist who can teach the patient how to relax their pelvic floor.

Natural oils (such as coconut oil or olive oil) can be effective lubricants.

Laser therapy may be useful for some women, for example, those who have had breast cancer.²² Salvatore and colleagues used the microablative fractional CO₂ laser in an uncontrolled study of seventy-seven postmenopausal women who had symptoms of vulvovaginal atrophy.²³ Twenty of these women had ceased sexual activity because of discomfort. The subjects had three treatments, each four weeks apart. A 'treatment' involved firing 'laser dots' over different areas of the vagina and vulva. This was very well tolerated without anaesthesia. At the twelve-week follow-up, seventeen out of twenty women who had ceased sexual activity because of pain were able to resume intercourse. Sexual function scores significantly improved over the study period.

Athanasiou and colleagues recently published a study examining the effect microablative fractional CO₂ laser on vaginal flora²⁴. At the end of a course of treatment, the vaginal pH fell and the prevalence of lactobacilli species increased. This novel therapy appears very promising, but further research is needed. Ideally a large, long-term (over years) randomized controlled trial is needed to confirm these results and to discover how long the therapeutic effect lasts.

Conclusions

Vulvovaginal atrophy after menopause is a major cause of distress for many post-menopausal women and their partners. Simple measures such as avoidance of soap and the use of moisturisers can help some. However, many need topical oestrogens such as Ovestin® or Vagifem® and oestriol pessaries. Ovestin® cream is best used by avoiding the applicator altogether and introducing a small amount of cream into the vagina with a finger and then smearing the residual cream onto the vulva. Vagifem® should ideally be introduced into the anterior portion of the vagina, and not deep into the fornices. For a small number of patients, the microablative fractional CO₂ laser may be helpful, although long-term studies are lacking.

Further Reading

Baber RJ, Panay N, Fenton A. 2016 *IMS Recommendations on women's midlife health and menopause hormone therapy*. Available online: <http://dx.doi.org/10.3109/13697137.2015.1129166>

Declaration

Dr John Eden was commissioned by Healthed for this article. The ideas, opinions and information presented are solely those of the author. Dr John Eden declares no significant competing financial, professional or personal interests that might influence this article.

References

- Gartoulla P, Worsley R, Bell RJ, Davis SR. *Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years*. *Menopause*. 2015 Jul; 22(7): 1-8
- Baber RJ, Panay N, Fenton A. 2016 *IMS Recommendations on women's midlife health and menopause hormone therapy*. *Climacteric* 2016 Apr; 19(2): 109-50. Available online: <http://dx.doi.org/10.3109/13697137.2015.1129166>
- de Villiers TJ, Hall JE, Pinkerton JV, Perez SC, Rees M, Yang C, et al. *Revised global consensus statement on menopausal hormone therapy*. *Climacteric* 2016 Aug; 19(4): 313-15.
- D'Amati G, di Gioia CR, Proietti Pannunzi L, Pistilli D, Carosa E, Lenzi A, et al. *Functional anatomy of the human vagina*. *J Endocrinol Invest* 2003; 26(3 Suppl): 92-6
- O'Connell HE, Eizenberg N, Rahman M, Cleeve J. *The anatomy of the distal vagina: towards unity*. *J Sex Med* 2008 Aug; 5(8): 1883-91
- Kim SO, Oh KJ, Lee HS, Ahn K, Kim SW, Park K. *Expression of aquaporin water channels in the vagina in premenopausal women*. *J Sex Med* 2011 Jul; 8(7): 1925-30
- Copas P, Bukovsky A, Asbury B, Elder RF, Caudle MR. *Estrogen, progesterone and androgen receptor expression in levator ani muscle and fascia*. *J Womens Health Gend Based Med* 2001 Oct; 10(8): 785-95
- Berman JR, Almeida FG, Jolin J, Raz S, Chaudhuri G, Gonzalez-Cadavid NF. *Correlation of androgen receptors, aromatase and 5- α reductase in the human vagina with menopausal status*. *Fertil Steril* 2003 Apr; 79(4): 925-31
- Ho MH, Bhatia NN, Bhasin S. *Anabolic effects of androgens on muscles of female pelvic floor and lower urinary tract*. *Curr Opin Obstet Gynecol* 2004 Oct; 16(5): 405-9
- Hodgins MB, Spike RC, Mackie RM, MacLean AB. *An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina*. *Br J Obstet Gynaecol* 1998 Feb; 105(2): 216-22.
- Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, et al. *Vaginal estrogen for genitourinary syndrome of menopause*. *Obstet Gynecol* 2014 Dec; 124(6): 1147-56
- Muhleisen AL, Herbst-Kralovetz MM. *Menopause and the vaginal microbiome*. *Maturitas* 2016 Sep; 91:42-50
- Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, Kusanovic JP, et al. *The vaginal microbiome: new information about genital tract flora using molecular based techniques*. *BJOG* 2001 Apr; 118(5): 533-49.
- Pacheco AR, Sperandio V. *Inter-kingdom signaling: chemical language between bacteria and host*. *Curr Opin Microbiol* 2009 Apr; 12(2): 192-8.
- Cicinelli E, De Ziegler D, Morgese S, Bulletti C, Luisi D, Schonauer LM. *'First uterine pass effect' is observed when estradiol is placed in the upper but not lower one third of the vagina*. *Fertil Steril* 2004 May; 81(5): 1414-6
- Cicinelli E. *Intravaginal oestrogen and progestin administration: advantages and disadvantages*. *Best Pract Res Clin Obstet Gynaecol* 2008 Apr; 22(2): 391-405
- Cicinelli E, Rubini G, De Ziegler D, Barba B, Pinto V, Di Stefano MG, et al. *Absorption and preferential vagina-to-uterus distribution after vaginal administration of 99mTc-pertechnetate in postmenopausal women*. *Fert Steril* 2001 Dec; 76(6): 1108-12
- Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, et al. *Vaginal estrogen for genitourinary syndrome of menopause*. *Obstet Gynecol* 2014 Dec; 124(6): 1147-56
- ACOG committee opinion. *The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer*. *Obstet Gynecol* 2016 Mar; 127(3): e93-6. Available online: <http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/The-Use-of-Vaginal-Estrogen-in-Women-With-a-History-of-Estrogen-Dependent-Breast-Cancer>
- Eden, J A. *DHEA replacement for postmenopausal women: placebo or panacea?* *Climacteric* 2015; 18(4): 439-40
- Labrie F, Martel C, Bérubé R, Côté I, Labrie C, Cusan L, et al. *Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens*. *J Steroid Biochem Mol Biol* 2013 Nov; 138: 359– 367
- Eden J. *Managing menopausal symptoms after breast cancer*. *Eur J Endocrinol* 2016 Mar; 174(3): R71-R77
- Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbini N et al. *Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy*. *Climacteric* 2015 Apr; 18: 219-225
- Athanasiou S, Pitsouni E, Antonopoulou S, Zacharakis D, Salvatore S, Falagas ME et al. *The effect of microablative fractional CO₂ laser on vaginal flora of postmenopausal women*. *Climacteric* 2016 Oct; 19(5): 512-8

Healthed 2017 Events

		
Sydney	International Convention Centre, Darling Harbour	February 18
Melbourne	Melbourne Convention & Exhibition Centre, South Wharf	March 4
Adelaide	Adelaide Convention Centre, North Terrace	May 20
Brisbane	Royal International Convention Centre, Bowen Hills	July 22
Perth	Perth Convention & Exhibition Centre, Perth	August 19

		
Sydney	Clancy Auditorium, University of New South Wales, Kensington	August 26
Adelaide	Adelaide Convention Centre, North Terrace	September 16
Melbourne	Melbourne Convention & Exhibition Centre, South Wharf	October 14
Brisbane	UQ Centre, University of Queensland, St Lucia	October 28
Perth	Perth Convention & Exhibition Centre, Perth	November 4

		
Sydney	Zenith Theatre, Chatswood	March 29
Melbourne	Melbourne Museum, Carlton	May 24
Brisbane	Translational Research Institute, Woollongabba	August 9

Upcoming Evening Seminars with Live Webcast		
Sydney	Infant Nutrition	June 20
Sydney	Travel Medicine	TBA
Sydney	Mental Health	TBA

See www.healthed.com.au for updates and more information.